Drug utilization study and safety evaluation based on prediction approach for drug interactions in chemotherapy

基于化疗药物相互作用预测方法的药物利用研究及安全性评价

• 批准号: 22790511
• 负责人: YOSHIDA Naoko
• 金额: $ 2.58万
• 依托单位: Kanazawa University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2010
• 资助国家: 日本
• 起止时间: 2010 至 2011
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22790511/
• 关键词: 医薬品副作用・相互作用; がん化学療法; 漢方薬; 安全性

The aim of this study was to describe utilization of anticancer drugs and concomitant medicines including Kanpo medicines, and evaluate safety of concomitant Kampo medicines in chemotherapy. As a result, Co-administration of Daikenchuto or Hangeshashinto, in patients treated with paclitaxel or irinotecan, respectively, showed significant association with decrease of platelet count over grade 3 based on Common Terminology Criteria for Adverse Events v4. 0 criteria. In addition, some of co-administrated Kampo medicines could affect occurrence of adverse effects, such as myelosuppression, electrolyte abnormality, or hepatic dysfunction.

本研究的目的是描述抗癌药物和包括汉方药物在内的伴随药物的使用，并评估化疗中伴随汉方药物的安全性。结果，分别接受紫杉醇或伊立替康治疗的患者联合服用 Daikenchuto 或 Hangeshashinto 与根据不良事件通用术语标准 v4 的 3 级以上血小板计数下降显着相关。 0 个标准。此外，一些汉方药物合用可能会影响不良反应的发生，如骨髓抑制、电解质异常或肝功能障碍。